Vendor, Corte Madera, CA
Ophirex, Inc.
UEI W452WY5E2JQ9, CAGE 7JTR0
2 awards and $3,885,532 obligated between March 19, 2024 and September 5, 2025, 100% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $3,885,532 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| W81XWH22C0030Definitive Contract, March 19, 2024, Full and Open Competition After Exclusion of Sources, 1 offers | Army Med Res Acq ActivityDefense Health Agency | Follow on Phase III Medical R&D SBIR for Project Titled Broad-Spectrum Snakebite Antidote Oral Product Development and IV Clinical StudyNAICS 541715, PSC AN13 | $4,530,514 |
| W81XWH20C0066Definitive Contract, September 5, 2025, Full and Open Competition After Exclusion of Sources, 1 offers | Army Med Res Acq ActivityDefense Health Agency | Targeting Spla2 for Treatment of Acute Respiratory Distress Syndrome Associated with Sars-Cov-2NAICS 541715, PSC AN94 | -$644,982 |
- Places of performance
- California
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental DevelopmentAN94 N – Health R&D Services
- Transactions
- 2 across 2 awards